Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

In our exclusive interview, Dr Moreau discussed key findings from an analysis of minimal residual disease negativity dynamics from IMROZ and the potential future implications of these findings for patients with newly diagnosed multiple myeloma who receive treatment with Isa-VRd.